FDA is making optimal use of its financial resources to maximize its ability to efficiently and effectively deliver on its commitments to the public.
Similar Posts
FDA Roundup: January 19, 2024
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.FDA Provides Guidance on Remote Interactive Evaluations for Oversight of Drug Facilities During COVID-19
FDA releases guidance on how remote interactive evaluations will be requested by FDA and conducted for the duration of COVID-19 at drug facilities.POSTPONED – 17th Annual Sentinel Initiative Public Workshop – 11/06/2025
The U.S. Food and Drug Administration, under a cooperative agreement with the Duke-Margolis Institute for Health Policy, is hosting the 16th Annual Sentinel Initiative Public Workshop on November 6, 2025Study of Sex Differences in the Clinical Evaluation of Medical Products
This guidance provides recommendations for increasing enrollment of females in clinical trials, analyzing and interpreting sex-specific data, and including sex-specific information in regulatory submissions of medical productsFind Information about a Drug
Information on FDA-approved drugs released for sale on the market, such as dosage, side effects, and disposal methodsCDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative